GHK-Cu
Also known as: Copper tripeptide-1, glycyl-L-histidyl-L-lysine copper, prezatide copper
Classification
Peptide
Regulatory Status
Overview
GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine discussed in skin remodeling and wound-biology literature; mechanisms are multi-pathway and mostly preclinical or cosmetic-context.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
ClassB source cannot establish canonical regulatory or safety fields. The statements below are retained as uncertainty, not as a label-backed verdict. | Regulatory status: not-established | Contraindication: Known copper sensitivity or Wilson disease contexts without clinician guidance | Warning: Topical irritation possible | Warning: Injectable gray-market GHK-Cu is not an approved systemic drug in this record | Precaution: Separate cosmetic evidence from systemic wellness marketing | Adverse effect: local skin irritation with topicals | Serious adverse effect: infection/sterility risk if injected from unapproved sources | Serious adverse effect: copper-related concerns in susceptible people
Pathways
extracellular matrix remodeling (research)
copper-peptide signaling in skin biology (research)
Interactions & cautions
Flagged in source data
unapproved injectable copper peptides stacked with other injectables
Drug interactions
high-dose copper supplements — Systemic copper load is not well quantified for many GHK-Cu products. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.